Ms Jones is Founder and Managing Partner of DNA Ink LLC, a life sciences advisory firm in San Francisco. Prior to starting her own firm, Ms. Jones spent 20 years at Genentech where she served in many roles in Immunology Research, Product Development and Business Development. During this time she managed Genentech's CD20 portfolio of assets, including Rituxan, the first monoclonal antibody launched to treat cancer, Ocrevus and Gazyva. Ms. Jones has very extensive networks within the pharmaceutical and biotech industry worldwide and the VC community in North America. Ms. Jones is a Non-Executive Director of Calithera Biosciences, Inc, a clinical-stage, precision oncology biopharmaceutical company focused on developing targeted therapies to refine treatment for biomarker specific populations. She is a member of the Risk Committee.
